By Ron Lanton III, Esq.
The U.S. Food and Drug Administration (FDA) has granted qualifying small pharmacy dispensers an additional year to comply with certain requirements under the Drug Supply Chain Security Act (DSCSA).
Announced on August 6, 2026, the exemption extends certain compliance requirements from November 27, 2026, to November 27, 2027.
The decision has implications for pharmacies, pharmaceutical manufacturers, wholesale distributors and companies providing drug supply chain technology.
Who Qualifies for the Extension?
FDA defines a qualifying small business dispenser based on the number of full-time pharmacists and qualified pharmacy technicians employed by the corporate entity that owns the dispenser.
To qualify, the entity must have 25 or fewer such employees as of November 27, 2026. The employee threshold applies across the corporate entity rather than to individual pharmacy locations.
Eligible dispensers do not need to submit a separate exemption request to FDA.
What Does the Extension Cover?
The exemptions address certain requirements involving:
Electronic exchange of drug transaction information.
Package-level product identification and verification.
Drug tracing systems and responses to regulatory investigations.
Certain verification requirements for suspect or illegitimate products.
Processing saleable returns involving qualifying small dispensers.
Other applicable DSCSA obligations remain in effect.
What Pharmaceutical Distributors and Manufacturers Should Know
The FDA announcement does not provide an industry-wide extension. Manufacturers, wholesale distributors and other affected trading partners must continue to comply with applicable DSCSA requirements except where specific exemptions apply.
Distributors serving qualifying pharmacies should review their customer agreements, data exchange capabilities, product return procedures and compliance policies.
Companies should also establish procedures for identifying which pharmacy customers qualify for the exemption and documenting transactions conducted under it.
Preparing for November 2027
Pharmacies should use the additional year to address technology costs, vendor agreements, employee training and operational readiness.
Businesses purchasing or acquiring pharmacies should also consider DSCSA compliance during due diligence. Technology investments, contractual obligations and changes in ownership or staffing could affect the cost and complexity of future compliance.
FDA has made clear that the exemptions are not intended to justify delaying implementation efforts.
How Lanton, Lanton & Sosa Law Can Help
Lanton, Lanton & Sosa Law advises pharmacies, pharmaceutical manufacturers, healthcare distributors and technology companies on regulatory compliance, commercial agreements, licensing, healthcare transactions and pharmaceutical supply chain requirements.
Our experience in pharmaceutical distribution and pharmacy law allows us to assist businesses with DSCSA compliance assessments, vendor and distribution agreements, regulatory matters and transaction due diligence.
Learn more about our Pharmacy Law, Pharmaceutical Law and Healthcare Distribution & Supply Chain Law practices.